MONTREAL, QUEBEC--(Marketwired - July 3, 2013) - IBEX Technologies Inc. (TSX VENTURE:IBT) today announces the grant of options to Richard Collin, CPA, CA, its newly appointed Director of Finance.
In connection with his appointment, Mr. Collin has been granted options to acquire up to 50,000 common shares of IBEX at an exercise price of $0.08 per common share for a term of 10 years pursuant to IBEX's incentive stock option plan.
The Company, through its wholly owned subsidiaries, IBEX Pharmaceuticals Inc. (Montreal, QC) and Bio-Research Products Inc. (North Liberty, IA), manufactures and markets enzymes for biomedical use. IBEX also manufactures and markets a series of arthritis assays which are widely used in osteoarthritis research.
For more information, please visit the Company's website at www.ibex.ca.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Stocks & Offerings
- Richard Collin
President & CEO
514-344-4004 x 143